Kinaxo, Bayer Vital Collaborate To Look for Cancer Treatment Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – The German biotech company Kinaxo Biotechnologies, a spinout of the Max Planck Institute, and Bayer Vital announced today that they have formed a collaboration to identify novel phosphoproteomics biomarkers for predicting cancer treatment outcomes.

The researchers plan to use Kinaxo's quantitative phosphoproteomics technology, PhosphoScout, to find and quantify phosphorylation sites as part of a clinical trial conducted by Bayer Vital on the use of oral anti-cancer drug sorafenib (Nexavar) in acute myeloid leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.